Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

ARNA 4.52
price chart
Zacks Rating on Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a hold, according to the latest average broker rating of 2.5. The number of analysts in this rating is 6. Research Analysts at Zacks has the shares a rating of 3, which implies that the firms recommendation ...
3 Sizzling Hot Biotech Stocks - Idera Pharmaceuticals Inc (NASDAQ:IDRA ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rose +1.80% to end last trading session at $4.52. The company, on June 16, 2015, released that Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer, has decided to leave the company ...
Company Shares of Arena Pharmaceuticals, Inc. Rally 1.14%
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rose by 1.14% in the past week and 1.83% for the last 4 weeks. In the past week, the shares has outperformed the S&P 500 by 2.34% and the outperformance increases to 2.62% for the last 4 weeks.
Analyst Price Target Update on Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): The mean estimate for the short term price target for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stands at $5.63 according to 4 Analysts. The higher price target estimate for the stock has been calculated at $8 ...
Fall in love with these 3 Biotech stocks - Arena Pharmaceuticals, Inc. (NASDAQ ...
Ms. Bielasz joined Arena in 2001 and is responsible for managing all accounting activities. Prior to joining Arena, Ms. Bielasz served as the controller of both public and private companies and began her career at KPMG LLP.
Healthcare Sector Update: KERX, IDRA, ARNA, CLDX  Wsnews4investors (press release) (blog)
Stock Insights on Arena Pharmaceuticals Inc (NASDAQ:ARNA)
[PRNewswire] Arena Pharmaceuticals Inc (NASDAQ:ARNA)(TREND ANALYSIS) announced that Robert E. Hoffman, Senior Vice President, Finance and Chief Financial Officer, has decided to leave the company after nearly 18 years of service to pursue ...
3 Biotech Stocks Are Getting Crushed – Arena Pharmaceuticals, Inc. (NASDAQ ...  Wall Street Observer
Stocks Plunging - Arena Pharmaceuticals (ARNA), Paragon Offshore (PGN ...  Investor Wired
Company Shares of Arena Pharmaceuticals, Inc. Drops by -0.68%
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has dropped 0.68% during the past week, however, the bigger picture is still very bullish; the shares have posted positive gains of 11.85% in the last 4 weeks.
Momentum Stock in Focus - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)  Enterprise Leader
Healthcare Sector Movers: Halozyme Therapeutics, Inc. (HALO), Arena ...  WallStreet Scope
Can Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Surprise Analysts this Quarter?
In the most recent quarter, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported an earnings surprise of 28.57% when the firm last announced their results for the period ending on 2015-03-31.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Price Target Update  OTC Outlook
Arena - Belviq Sales Slide Again
Arena (NASDAQ:ARNA) investors did not have much to celebrate going into the holiday weekend when it comes to Belviq sales.
Biotech Stocks getting no love - Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Mr. Hoffman is expected to remain in his current role at Arena until July 10, 2015. “Robert has been a valuable member of our management team and, on behalf of myself and the company, I thank him for his years of leadership and service to Arena,” said ...